RU2011118362A - Онкостатин как усилитель иммуностимулирующей активности человеческих эпителиальных клеток - Google Patents

Онкостатин как усилитель иммуностимулирующей активности человеческих эпителиальных клеток Download PDF

Info

Publication number
RU2011118362A
RU2011118362A RU2011118362/10A RU2011118362A RU2011118362A RU 2011118362 A RU2011118362 A RU 2011118362A RU 2011118362/10 A RU2011118362/10 A RU 2011118362/10A RU 2011118362 A RU2011118362 A RU 2011118362A RU 2011118362 A RU2011118362 A RU 2011118362A
Authority
RU
Russia
Prior art keywords
treatment
osm
epithelial cells
type
ifn
Prior art date
Application number
RU2011118362/10A
Other languages
English (en)
Russian (ru)
Inventor
АРРЕГИ Рафаэль АЛЬДАБЕ (ES)
АРРЕГИ Рафаэль АЛЬДАБЕ
ДЕ ЛА ТАХАДА Ирансу ГОНСАЛЕС (ES)
ДЕ ЛА ТАХАДА Ирансу ГОНСАЛЕС
ЛЕОС Мария Эстер ЛАРРЕА (ES)
ЛЕОС Мария Эстер ЛАРРЕА
ВАЛЬТУЭНЬЯ Хесус Мария ПРЬЕТО (ES)
Вальтуэнья Хесус Мария Прьето
УГАРРИСА Пабло САРОБЕ (ES)
УГАРРИСА Пабло САРОБЕ
Original Assignee
Проекто Де Биомедисина Сима, С.Л. (Es)
Проекто Де Биомедисина Сима, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Проекто Де Биомедисина Сима, С.Л. (Es), Проекто Де Биомедисина Сима, С.Л. filed Critical Проекто Де Биомедисина Сима, С.Л. (Es)
Publication of RU2011118362A publication Critical patent/RU2011118362A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2011118362/10A 2008-10-07 2009-10-06 Онкостатин как усилитель иммуностимулирующей активности человеческих эпителиальных клеток RU2011118362A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200802835 2008-10-07
ES200802835A ES2342529B1 (es) 2008-10-07 2008-10-07 Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.

Publications (1)

Publication Number Publication Date
RU2011118362A true RU2011118362A (ru) 2012-11-20

Family

ID=41478601

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011118362/10A RU2011118362A (ru) 2008-10-07 2009-10-06 Онкостатин как усилитель иммуностимулирующей активности человеческих эпителиальных клеток

Country Status (11)

Country Link
US (1) US20110195047A1 (cg-RX-API-DMAC7.html)
EP (1) EP2345423A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012504948A (cg-RX-API-DMAC7.html)
CN (1) CN102202690A (cg-RX-API-DMAC7.html)
AU (1) AU2009301067A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0920662A2 (cg-RX-API-DMAC7.html)
CA (1) CA2739670A1 (cg-RX-API-DMAC7.html)
ES (1) ES2342529B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011003676A (cg-RX-API-DMAC7.html)
RU (1) RU2011118362A (cg-RX-API-DMAC7.html)
WO (1) WO2010040882A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102352368B (zh) * 2011-09-29 2013-12-04 苏州大学 Ing4与osm双基因共表达载体及其应用
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
WO2014198995A1 (es) * 2013-06-14 2014-12-18 Universidad De Granada Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas
WO2015089380A2 (en) * 2013-12-12 2015-06-18 Celcuity Llc Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
CN104096219A (zh) * 2014-07-08 2014-10-15 武汉大学 Ⅱ型抑瘤素m受体（osmr）在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
CA3049472A1 (en) 2017-03-20 2018-09-27 Celcuity Inc. Methods of measuring signaling pathway activity for selection of therapeutic agents
AU2021364308A1 (en) 2020-10-19 2023-05-18 Zoetis Services Llc Antibodies to canine and feline oncostatin m receptor beta and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
ATE174223T1 (de) 1989-04-10 1998-12-15 Oncogen Verwendung von oncostatin m zur suppression von mhc antigenen
ATE412433T1 (de) * 1999-02-12 2008-11-15 Scripps Research Inst Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
ES2292619T3 (es) * 2000-09-15 2008-03-16 Ortho-Mcneil Pharmaceutical, Inc. Composiciones y metodos para inducir respuestas citologicas especificas de la celula t.
JP2004026768A (ja) 2002-06-27 2004-01-29 Kanagawa Acad Of Sci & Technol 肝疾患治療又は予防薬
AU2002953238A0 (en) * 2002-12-09 2003-01-02 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland In vitro immunization
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CA2593648A1 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
AU2006210606B2 (en) 2005-02-03 2012-03-22 Macrogenics West, Inc. Antibodies to Oncostatin M receptor
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.

Also Published As

Publication number Publication date
CN102202690A (zh) 2011-09-28
US20110195047A1 (en) 2011-08-11
ES2342529B1 (es) 2011-05-11
ES2342529A1 (es) 2010-07-07
EP2345423A1 (en) 2011-07-20
MX2011003676A (es) 2011-05-02
AU2009301067A1 (en) 2010-04-15
JP2012504948A (ja) 2012-03-01
WO2010040882A1 (es) 2010-04-15
CA2739670A1 (en) 2010-04-15
BRPI0920662A2 (pt) 2018-06-26

Similar Documents

Publication Publication Date Title
Yasamineh et al. Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19
RU2011118362A (ru) Онкостатин как усилитель иммуностимулирующей активности человеческих эпителиальных клеток
AU2012280322B2 (en) Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
US20200360497A1 (en) Compositions and methods for producing dendritic cells
Dong et al. Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice
JP2019520061A5 (cg-RX-API-DMAC7.html)
US10918704B2 (en) Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
JP2013535218A5 (cg-RX-API-DMAC7.html)
JP2012504948A5 (cg-RX-API-DMAC7.html)
JP2008539751A (ja) 新規組成物およびその使用
JP2018522880A (ja) デングウイルス及び樹状細胞による併用療法のための組成物及び方法
RU2458985C1 (ru) Способ генерации антиген-специфических цитотоксических клеток с противоопухолевой активностью
US20170216354A1 (en) Clinically useful non-antigen pulsed dendritic cells
EP1959007A1 (en) Method for providing mature dendritic cells
CN118384269A (zh) 阿托伐他汀钙在制备增强树突状细胞疫苗抗肿瘤制剂中的应用
JP5303113B2 (ja) 癌ワクチン
Khamisabadi et al. Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice
RU2508298C2 (ru) Способ генерации антиген-специфических цитотоксических клеток с активностью против клеток рака яичника
EP2050455B1 (en) Compounds leading to an increase of the IL-12/IL-10 ratio and their use for therapy of infectious and proliferative diseases
JP2020505050A (ja) 免疫寛容性プラズマサイトイド樹状細胞及びその製造方法
KR20200144060A (ko) 건강한 사람의 면역세포 배양액을 이용한 nk 세포의 함량을 증진시키는 방법
Mousavi Jahed et al. Application of Regenerative Medicine in the Treatment and Management of COVID-19.
Garlie et al. Enrichment of CD14+ Cells for Dendritic Cell Production Using the Elutra™ Cell Separation System
Faries et al. Intralesional Bacille Calmette-Guerin in melanoma: a forgotten modality of in situ immunization
CN105219725A (zh) 一种用于激活肉瘤特异性免疫反应的试剂盒